Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $9.8 Million Underwritten Offering of BiondVax Pharmaceuticals Ltd.
Press Release – New York, NY – December 30, 2021 – Sichenzia Ross Ference LLP today announced that it represented Aegis Capital Corp. as sole book runner in an underwritten public offering of BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV). The offering included 4,144,068 American Depositary Shares (“ADSs”) sold to the public at $2.36 per ADS. The gross proceeds of the offering to the company were approximately $9.8 million.
The offering was made pursuant to an effective shelf registration statement on Form F-3 (No. 333-2401889) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on August 10, 2020. The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Darrin M. Ocasio and Avital Perlman, counsel Jennifer Trowbridge, associate Zachary Weiss and senior paralegal Raquel Vasquez.
- Sichenzia Ross Ference LLP Team Featured in China Business Law Journal - March 29, 2023
- Sichenzia Ross Ference LLP Represents Spartan Capital Securities, LLC in a $1.25 Million U.S. Private Placement of Alpha Cognition, Inc. - March 16, 2023
- Sichenzia Ross Ference LLP Represents EzFill Holdings, Inc., in $2,096,000 At-The-Market Offering Facility - March 3, 2023